London
· Delayed Price · Currency is GBP · Price in GBX N4 Pharma Statistics
Total Valuation
N4 Pharma has a market cap or net worth of GBP 3.95 million. The enterprise value is 3.33 million.
| Market Cap | 3.95M |
| Enterprise Value | 3.33M |
Important Dates
The next estimated earnings date is Tuesday, June 24, 2025.
| Earnings Date | Jun 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
N4 Pharma has 832.28 million shares outstanding. The number of shares has increased by 40.34% in one year.
| Current Share Class | 832.28M |
| Shares Outstanding | 832.28M |
| Shares Change (YoY) | +40.34% |
| Shares Change (QoQ) | +13.25% |
| Owned by Insiders (%) | 23.82% |
| Owned by Institutions (%) | 35.45% |
| Float | 482.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 542.89 |
| PB Ratio | 6.07 |
| P/TBV Ratio | 6.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.15 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.24
| Current Ratio | 6.24 |
| Quick Ratio | 6.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -121.41% and return on invested capital (ROIC) is -82.73%.
| Return on Equity (ROE) | -121.41% |
| Return on Assets (ROA) | -74.42% |
| Return on Invested Capital (ROIC) | -82.73% |
| Return on Capital Employed (ROCE) | -187.46% |
| Revenue Per Employee | 1,456 |
| Profits Per Employee | -211,724 |
| Employee Count | 5 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.00% in the last 52 weeks. The beta is 0.71, so N4 Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -24.00% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 55.24 |
| Average Volume (20 Days) | 1,117,490 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, N4 Pharma had revenue of GBP 7,282 and -1.06 million in losses. Loss per share was -0.00.
| Revenue | 7,282 |
| Gross Profit | 7,282 |
| Operating Income | -1.22M |
| Pretax Income | -1.22M |
| Net Income | -1.06M |
| EBITDA | n/a |
| EBIT | -1.22M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 625,972 in cash and n/a in debt, giving a net cash position of 625,972 or 0.00 per share.
| Cash & Cash Equivalents | 625,972 |
| Total Debt | n/a |
| Net Cash | 625,972 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 651,402 |
| Book Value Per Share | 0.00 |
| Working Capital | 651,402 |
Cash Flow
| Operating Cash Flow | -971,500 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -16,768.76% |
| Pretax Margin | -16,768.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
N4 Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.34% |
| Shareholder Yield | -40.34% |
| Earnings Yield | -26.78% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |